GlassScriptPhysician profile
Ron Kenneth Lord
NPI 1790991107
$61,347.41
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $2,597 · 2021: $239 · 2022: $12K · 2023: $12K · 2024: $17K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $16K · Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,333.34 |
| Consulting Fee | $16,333.33 |
| Food and Beverage | $1,424.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $40,000.01 | 2022-2024 | |
| Glaukos Corporation | $16,364.51 | 2021-2025 | Istent Infinite, Travoprost Intraocular Implant - Idose |
| Allergan, INC. | $1,735.80 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $932.37 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $484.33 | 2019-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $415.95 | 2020 | |
| Carl Zeiss Meditec, INC. | $392.13 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $213.27 | 2023-2025 | Syfovre |
| Abbvie INC. | $186.92 | 2022-2025 | |
| Astellas Pharma US INC | $129.30 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $129.01 | 2020-2021 | |
| Eyepoint US, INC. | $108.01 | 2019-2021 | |
| Alimera Sciences, INC. | $52.33 | 2024 | Iluvien, Yutiq |
| Genentech, INC. | $41.58 | 2023 | Vabysmo |
| Coherus Oncology, INC. | $34.83 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $33.33 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.14 | 2019 | |
| Dutch Ophthalmic, USA | $24.62 | 2021 | |
| Spark Therapeutics, INC. | $22.80 | 2021 | |
| Harrow Eye, LLC | $21.17 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.